WASHINGTON, March 19, 2017 /PRNewswire/ -- New late-breaking
featured clinical research presented today adds strong clinical
support for Abbott's CardioMEMS™ HF System as an
effective real-world approach to reduce heart failure
hospitalizations and combat the rising cost of heart failure. The
CardioMEMS HF System is the first and only U.S. Food and Drug
Administration-approved monitor that, when used by physicians to
manage heart failure, has been shown to significantly reduce heart
failure hospital admissions and improve the quality of life in
patients with heart failure (NYHA Class III). The latest research
includes more than 1,100 Medicare patients and was presented today
during the American College of Cardiology (ACC) 66th
Annual Scientific Sessions in Washington, D.C., and simultaneously published
in the Journal of the American College of Cardiology
(JACC).
Researchers found a 46 percent reduction in heart failure
hospitalizations in patients six months after receiving the
CardioMEMS HF System, and a 34 percent reduction at 12 months
post-implant. The data are consistent with what was seen in the
CHAMPION clinical trial, further confirming that when physicians
adjust medications based on the patient's pulmonary artery
pressures, related hospitalizations are significantly reduced.
"These results support the clinical effectiveness and potential
cost savings of using an implantable hemodynamic monitor to help
with heart failure management," said Akshay
Desai, M.D., director of the Heart Failure Disease
Management Program at Brigham and Women's Hospital in Boston, Mass. "Reducing heart failure
hospitalizations is an important goal for patients and hospitals
alike, and may help to improve long-term clinical outcomes and
quality of life for our patients."
The data also showcased important cost-savings captured through
reductions in heart failure hospitalizations associated with the
use of the CardioMEMS HF System. In particular, in the six months
post-implant, each patient had an average reduction of more than
$10,500 in comprehensive health care
costs compared to the six months prior to implant. Twelve month
post-implant analysis showed a $13,190 reduction in costs per patient.
"The reduction in hospitalizations and costs associated with
heart failure confirmed by these data shows that proactive patient
management with the CardioMEMS HF System is successful in
mainstream practice and results in improved clinical outcomes,"
said Philip Adamson, M.D., medical
director of Abbott's heart failure business. "Success with this
technology for us means helping patients get back to living their
life."
Data were collected using U.S. Medicare claims from patients
undergoing a CardioMEMS sensor implant to measure pulmonary artery
pressure, and the rates of heart failure hospitalizations from
before and after the implant were compared. Comprehensive heart
failure-related costs were also compared. The data confirmed that
hemodynamic (pulmonary artery pressure) monitoring with the
CardioMEMS HF System in an outpatient setting reduced heart failure
hospitalization for patients while also reducing related costs.
Additional data on managing heart failure patients with the
CardioMEMS HF System published on Feb. 22,
2017, in Circulation—Impact of Practice Based
Management of PA Pressures in 2,000 Patients Implanted with the
CardioMEMS Sensor—showed that patient compliance and
physician-directed management outside of a clinical study led to a
significant reduction of pulmonary artery pressures.
About Abbott's Heart Failure Portfolio:
Abbott is
pioneering heart failure disease management with innovative
solutions like the CardioMEMS HF System, ground-breaking
quadripolar pacing technology, our first-to-market
MultiPoint™ pacing technology and, in select European
markets, the HeartMate™ 3 left ventricular assist
system. Abbott collaborates with heart failure specialists,
clinicians and advocacy partners to provide innovative,
cost-effective solutions that help reduce hospitalizations and
improve patient quality of life for heart failure patients around
the world.
About Abbott:
At Abbott (NYSE: ABT), we're committed
to helping people live their best possible life through the power
of health. For more than 125 years, we've brought new products and
technologies to the world -- in nutrition, diagnostics, medical
devices and branded generic pharmaceuticals -- that create more
possibilities for more people at all stages of life. Today, 94,000
of us are working to help people live not just longer, but better,
in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/late-breaking-data-shows-the-cardiomems-hf-system-is-effective-in-reducing-heart-failure-hospitalizations-and-cost-of-care-300425696.html
SOURCE Abbott